TapImmune Inc. is a development stage company who engages in the discovery and development of immunotherapeutics for the treatment of cancer, as well as therapies for infectious diseases, autoimmune disorders, and transplant tissue rejection. The company is also involved in the development of HER2/neu, a vaccine technology, which is currently in Phase I human clinical trials for the treatment of breast cancer. Its products also include TAP cancer vaccine, which is under preclinical toxicology and clinical manufacturing studies for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company has a technology option agreement with the Mayo Foundation for the evaluation of HER2/neu, as well as a research license and option agreement with Crucell Holland B.V. TapImmune Inc. was founded in 1999 and is based in Seattle, Washington.